- Home
- OGN vs CPRX Comparison
OGN vs CPRX Comparison
Compare OGN & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGN
- CPRX
- Stock Information
- Founded
- OGN 1923
- CPRX 2002
- Country
- OGN United States
- CPRX United States
- Employees
- OGN N/A
- CPRX N/A
- Industry
- OGN Biotechnology: Pharmaceutical Preparations
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- OGN Health Care
- CPRX Health Care
- Exchange
- OGN Nasdaq
- CPRX Nasdaq
- Market Cap
- OGN 2.7B
- CPRX 2.6B
- IPO Year
- OGN N/A
- CPRX 2006
- Fundamental
- Price
- OGN $10.45
- CPRX $20.02
- Analyst Decision
- OGN Hold
- CPRX Strong Buy
- Analyst Count
- OGN 4
- CPRX 5
- Target Price
- OGN $18.00
- CPRX $33.20
- AVG Volume (30 Days)
- OGN 3.6M
- CPRX 1.5M
- Earning Date
- OGN 10-30-2025
- CPRX 11-05-2025
- Dividend Yield
- OGN 0.76%
- CPRX N/A
- EPS Growth
- OGN N/A
- CPRX 183.96
- EPS
- OGN 2.69
- CPRX 1.65
- Revenue
- OGN $6,281,000,000.00
- CPRX $558,499,000.00
- Revenue This Year
- OGN N/A
- CPRX $16.51
- Revenue Next Year
- OGN $1.36
- CPRX $9.58
- P/E Ratio
- OGN $3.90
- CPRX $12.10
- Revenue Growth
- OGN N/A
- CPRX 28.55
- 52 Week Low
- OGN $8.01
- CPRX $19.15
- 52 Week High
- OGN $20.96
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- OGN 61.42
- CPRX 46.35
- Support Level
- OGN $10.24
- CPRX $19.66
- Resistance Level
- OGN $10.72
- CPRX $20.52
- Average True Range (ATR)
- OGN 0.40
- CPRX 0.67
- MACD
- OGN 0.07
- CPRX 0.03
- Stochastic Oscillator
- OGN 74.23
- CPRX 42.08
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).